**ABS Conference
13th & 14th May 2019, SEC Glasgow**

**Abstracts for poster presentation**

*(Posters will be allocated to a discussion session. Further information will follow on these).*

**P001. An audit of patients undergoing neoadjuvant chemotherapy and analysis of nodal disease to guide management**
Eva Nagy

**P002. One Step Nucleic Acid Amplification Sentinel Lymph Node sampling as a predictor of axillary node status in early invasive breast cancer: a UK single centre experience**
Ellen Jerome

**P003. Efficacy of immediate axillary clearance (AC) in Metasin positive sentinel lymph node (SLN) biopsy assay: A large single centre experience**
Nikolaos Marikakis

**P004. Intraoperative assessment of sentinel nodes in mastectomy patients**
Sadaf Jafferbhoy

**P005. Axillary radiotherapy is non inferior to completion axillary clearance in patients with positive sentinel lymph node biopsy - a single-centre observational cohort study**
Darja Kremel

**P006. Does the Total Tumour Load (TTL) as detected by One Step Nucleic Acid Amplification (OSNA) predict Non Sentinel Node Positivity?**
Mandana Pennick

**P007. Radiological versus pathological response of the axilla to neoadjuvant chemotherapy: Assessing the accuracy of MRI response prediction**
Ross McLean

**P008. Impact of Sentinel Lymph Node Biopsy on Physical Function of the Upper Limb – A Prospective Study in Patients with Early Breast Cancer**
Mihir Chandarana

**P009. Does total tumour load in Sentinel lymph node biopsy assessed by OSNA predict further axillary node disease? Can it stratify which patients may benefit from axillary clearance?**
Adrian McKenna

**P010. A Prospective Comparative Study Of Sentinel Lymph Node Biopsy With Indo-Cyanine Green (ICG) Florescence Technique versus Dual Dye Technique for Early Breast Cancer - Going Beyond the Horizon in India.**
Shaziya Hassan Ali

**P011. Axillar management after Neo-adjuvant chemotherapy ; Edinburgh Breast Unit 2016-17period**
Teresa Fernandez

**P012. The role of sentinel lymph node biopsy in planning adjuvant chemotherapy for elderly women with low risk breast cancer.**
Vivienne Blackhall

**P013. Magnetic seeds: an attractive localisation option for the management of axillary node positive breast cancer**
Victoria Sinnett

**P014. Comparison of axillary node sampling and sentinel lymph node biopsy before and after the introduction of Sentimag® magnetic tracer technology**
Bahar Mirshekar-Syahkal

**P015. Outcomes following neoadjuvant chemotherapy for breast cancer: pathological response in the axilla**
Ross McLean

**P016. Can we use OSNA (One Step Nucleic acid Amplification) routinely in DCIS? – A single centre study**
Uma Sridharan

**P017. ACCURACY OF PREOPERATIVE ULTRASOUND STAGING OF THE AXILLA. A SINGLE INSTITUTE EXPERIENCE IN THE UK**
Alaa Talaat

**P018. Impact of Neoadjuvant Chemotherapy on Axillary Tumour Burden**
Paran Kiritharamohan

**P019. Factors associated with complete pathological response in the axilla following primary chemotherapy**
Alison Luther

**P020. The Use of Intraoperative Lymph Node Analysis with Neoadjuvant Chemotherapy: A three-year retrospective cohort study**
James Olivier

**P021. Axillary complete pathological response to neo-adjuvant chemotherapy in breast cancer, can we predict it?**
Ghassan Elamin

**P022. Re-audit of Accuracy of Axillary Ultrasound Scan in detecting Metastatic Lymph Node Involvement in Breast Cancer Patients**
Tin SEIN

**P023. Is axillary clearance needed for all node-positive patients who are having neoadjuvant chemotherapy?**
Zaid Al-Ishaq

**P024. Axillary management after Neoadjuvant Chemotherapy in node positive breast cancer.**
Adrian McKenna

**P025. Should we do sentinel lymph node biopsy after neoadjuvant chemotherapy?**
Masuma Sarker

**P026. Is the response to Neoadjuvant chemotherapy in locally advanced breast cancer homogenous and predictable ?**
Diptendra Kumar Sarkar

**P027. The unexpected unpleasant surprise: Malignancy on histopathology following duct excision surgery- is it avoidable?**
Christopher Cartlidge

**P028. Vitamain D deficiency in mastalgia : is it a coincidence or an association ?**
Diptendra Kumar Sarkar

**P029. Does every young woman presenting with a solid breast lump require a biopsy?six year experience of a regional breast unit**
Heather Rose

**P030. Retrospective review of benign phyllodes cases to analyse treatment, follow-up practice and factors predictive of local recurrence.**
Pooja Padmanabhan

**P031. Patterns of self-referral for breast cancer screening in women aged over 70 in Wales between 2005 and 2016**
Anna Powell-Chandler

**P032. Review of breast cancer diagnoses in women aged over 70 years in Wales: A comparison between screen-detected and symptomatic presentations between 2010-2012 with 5 year follow-up**
Anna Powell-Chandler

**P033. The Impact of Community Outreach Black and Ethnic Minority Breast Health Awareness Seminar: Addressing healthcare inequalities**
Philippa Jackson

**P034. Review of our initial use of tomosynthesis-guided biopsy - How did it help? Dr Eman Hafez, Mrs Dianne Lennox, Dr Nerys Forester**
Eman Hafez

**P035. Comparison of post-operative patient satisfaction and health-related quality of life following latissimus dorsi (LD) flap breast reconstruction, deep inferior epigastric perforator (DIEP) flap breast reconstruction and bilateral therapeutic mammoplasty us**
Joanna Wolska

**P036. Predictors of Non-Sentinel Node Metastasis and Poorer Patient Response to Neoadjuvant Chemotherapy in Primary Breast Cancer: A 10-Year Study**
Sam Jenkins

**P037. Magseed localisation of non palpable breast cancer. Is the future magnetic?**
Konstantinos Zacharioudakis

**P038. An Objective Aesthetic Outcome Tool using 3-Dimensional Surface Imaging (3D-SI) to Replace Panel Assessment for Breast Conserving Treatment (BCT).**
Amy Godden

**P039. Lavage combined with minimally invasive surgery in treatment of plasma cell mastitis: A clinical study**
Hongli Wu

**P040. Radiological and surgical efficacy of neoadjuvant single vs dual blockade in HER 2 positive breast cancer and its impact on surgical planning: A retrospective single centre study.**
Aishah Hakim

**P041. Do waiting times for surgery have an impact on breast cancer tumour sizes?**
Yazan Masannat

**P042. Evaluation of a Breast Cancer Survivorship Programme: 7-year patient outcomes and service experience**
Kimberley Edwards

**P043. Skin sparing mastectomy with immediate dermal sling implant reconstruction: an assessment of outcomes and patient satisfaction**
Frederick hartley

**P044. Clinico-pathological correlates of Triple Negative Breast Cancer and factors affecting Disease Free Survival- Experience from a tertiary care centre**
Ishita Laroiya

**P045. Shoulder function following latissumus dorsi flap reconstruction with perioperative regional block**
Maurice Samake

**P046. Assessment of Rates of Local Recurrence in a Symptomatic Centre Following Breast Cancer Surgery**
Sarah Michael

**P047. Dermal flap and implant-based reconstruction- a useful technique**
Rashmi Verma

**P048. Interim analysis of an evaluation of clinical service impact of switching from wire to magnetic seeds for localisation of impalpable breast lesions for surgery.**
Aikaterini Micha

**P049. Outcomes of breast cancer management from an urban specialist breast centre in South India**
Naga Amulya Mullapudi

**P050. Perioperative management of anticoagulation in high-risk breast surgery patients: development of a multidisciplinary consensus pathway**
Kian Tan

**P051. Clinico-pathological features of Synchronous Breast Cancers in Northern Ireland, 2000-2015**
Gary Dobson

**P052. Management of Occult Breast Cancer (T0N1/2/3): What is the evidence?**
John Wild

**P053. Management of patients over the age of 80 diagnosed with breast cancer: A single centre experience of treatment options and long term outcomes.**
Christine Blane

**P054. Emergency readmissions after breast surgery: can we trust Model Hospital?**
Ayesha Dalal

**P055. Day-Case Mastectomy Target- Achievable and Sustainable for the Future of the NHS**
Claudia Wilson

**P056. Comparison of post Neoadjuvant MRI and Histology results**
Sadaf Jafferbhoy

**P057. Positive axillary node biopsy in early breast cancer. Can patients avoid axillary clearance?**
Syeda Masooma Zaidi

**P058. Deep Inferior Epigastric Perforator Flap for Breast Reconstruction: Audit of 8-year Single Trust Experience**
Kenny Kin Lun Lau

**P059. Wearable Sensing for Quantification of Upper Limb Morbidity and Recovery After Breast and Axillary Surgery – a Pilot Feasibility Trial**
Richard Kwasnicki

**P060. Clinical outcomes and trainee evaluation of intraoperative ultrasound guided localisation of impalpable breast lesion (IOL) training in the Cambridge Breast Unit (CBU)**
Primeera Wignarajah

**P061. Effect of Povidone- Iodine dressings on surgical site infection rate: A Randomised Controlled Trial**
Lay In Lim

**P062. An audit of prepectoral breast reconstructions using the Braxon® acellular dermal matrix (ADM).**
Paige Bishop

**P063. Is Sentinel lymph node biopsy (SLNB) required prior to mastectomy and implant-based reconstruction (IBR)?**
Barbra Kittel

**P064. Does selective use of MRI in neoadjuvant setting facilitates surgical decision making?**
Bo Yuan Khor

**P065. Neo-Adjuvant Chemotherapy In A Semi-Rural District General Hospital: Why Not?**
Kelvin Gomez

**P066. Implant Based Reconstruction: An Audit of Practice in a Semi-Rural District General Hospital**
Kelvin Gomez

**P067. Outcomes following neoadjuvant chemotherapy at a district general hospital.**
Katie Miller

**P068. Audit of early complications after implant only reconstructions in a single unit over 8 years demonstrating no difference whether the nipple is conserved or not.**
Siobhan Laws

**P069. Simultaneous bilateral mastectomies**
Samreen Khan

**P070. Is there any role of pre-operative breast MRI on breast cancer treatment planning?**
Masuma Sarker

**P071. The investigation and management of unilateral nipple discharge by breast units across Wessex.**
Sarah Clark

**P072. Synchronous cancers following MRI in Neoadjuvant Chemotherapy**
Sadaf Jafferbhoy

**P073. Patients receiving neoadjuvant chemotherapy for breast cancer do not require routine staging investigations**
Petros Amorginos

**P074. Spectrum of paediatric breast health issues : a beginner’s appraisal**
Agnimita Giri Sarkar

**P075. Assessing the value of preoperative MRI in guiding diagnostic and surgical management of breast cancer patients.**
Christine Xue

**P076. After the Neosphere trial: the realities of planning treatment. An audit of HER2 status availability for the initial diagnostic multi-disciplinary meetings in patients with newly diagnosed invasive breast cancers**
Christie Brennan

**P077. Patient Satisfaction with a new Vacuum Assisted Biopsy (VAB) Service in a District General Hospital**
Rachel Bright-Thomas

**P078. One third of all referrals to find 1% with cancer: a cross-sectional study of clinical presentation in women under 40 referred to a UK breast clinic**
Jennifer McIlhenny

**P079. Variation in the Work Up and Management of Patients with Gynaecomastia**
Zofia Zielicka

**P080. The efficacy of systemic staging for detection of distant metastases in newly diagnosed breast cancer and its impact on patient management: two breast units review on practice.**
Christina Yip

**P081. A Trust-Wide Breast Abscess Management and Referral Pathway**
Radhika Merh

**P082. Establishing Specialist Breast Care in Malawi: towards a national breast service.**
Briony Ackroyd-Parkin

**P083. Shared Decision-Making and Digital Accessibility Of Patients Undergoing Breast Surgery**
Edward St John

**P084. Correlation between surgeon (intra-operative) and pathologist (post-operative) tissue orientation in breast conserving surgery**
Ahmed Ezzat

**P085. The use of the Klinitray: Is it cost-effective?**
Mina Awad

**P086. Pathological response in the breast following dual anti-HER2 neoadjuvant chemotherapy for breast cancer**
Ross McLean

**P087. Response to Neoadjuvant Chemotherapy in Node-Positive Non-Inflammatory Breast Cancer**
Siún Walsh

**P088. Breast cancer patients with no surgery in the breast after an exceptional response to neoadjuvant chemotherapy: a case series.**
Victoria Teoh

**P089. Neoadjuvant Pertuzumab in the treatment of HER2+ve breast cancer: Increased Pathological Complete Response, but at a cost?**
Jamie Vatish

**P090. How accurate is ultrasound scan in predicting the size of residual breast cancer following neoadjuvant chemotherapy?**
Ojas Pujji

**P091. Oncotype DX, Predict, and the Nottingham Prognostic Index (NPI) – A study in decision making**
Hirah Rizki

**P092. EFFECT OF EXERCISE IN BREAST CANCER PATIENTS TAKING AROMATASE INHIBITORS**
Ibrahim El Zayat

**P093. Outcomes following neoadjuvant chemotherapy for breast cancer**
Ross McLean

**P094. Retrospective Review of Intermediate Oncotype-DX Recurrence Scores Used to Influence Adjuvant Chemotherapy in a Large Breast Unit**
Alexander O'Connor

**P095. The relationship between cardiac dosimetry and tumour quadrant location in left sided whole breast and chest wall adjuvant radiotherapy**
Gabija Lazaraviciute

**P096. An audit of the role of PONDx in chemotherapy decision-making in the breast MDT**
Hazem Khout

**P097. The Impact of TAILORx study on the recommendation of chemotherapy- the Warwick experience**
Tin SEIN

**P098. Audit of Neoadjuvant Chemotherapy in management of breast cancer – our unit experience**
Shihanie Rubecka Dissanayake

**P099. Is there a need for a Secondary Breast Cancer Nurse Specialist in Northern Ireland?**
Glenda Paget

**P100. Health and Wellbeing Events are a valued contribution to a breast cancer patient’s recovery and survivorship.**
Glenda Paget

**P101. Breast Open Access Follow-Up Patient Satisfaction Audit**
Sarah Anne Brewer

**P102. The benefits of a nurse-led bra fitting service to breast oncology patients in their post-operative recovery**
Georgette Oni

**P103. Do our ”Feel More Like Yourself” sessions have a lasting effect on breast cancer patients feelings of self-esteem and self confidence**
rachael willetts

**P104. Evaluating Aesthetic Outcome for Breast Reconstruction; a Delphi Consensus Process for Expert Panel Assessment as a Baseline for an Objective Aesthetic Assessment Tool.**
Amy Godden

**P105. A service evaluation of data transfer within a regional complex autologous free-flap reconstruction service**
Muneer Ahmed

**P106. Appropriately-designed randomised trials may be an acceptable method for addressing uncertainties implant-based breast reconstruction: Preliminary findings from the iBRA Randomisation Acceptability Survey**
Shelley Potter

**P107. A systematic review and meta-analysis of the clinical and quality of life outcomes of immediate and delayed autologous microvascular flap-based breast reconstruction in the context of radiotherapy**
Ankur Khajuria

**P108. Extreme oncoplastic conservation is a safe new alternative to mastectomy**
Belinda Pearce

**P109. Primary Radiotherapy And Deep inferior epigastric artery perforator (DIEP) flAp study (PRADA): Aesthetic Outcome and Patient Satisfaction at one year.**
Amy Godden

**P110. Partial breast reconstruction (PBR) with Lateral Chest Wall Perforator Flaps (CWPF) to facilitate breast conservation surgery (BCS) in women with breast cancer: A single center experience over 7 years and report on follow-up and patient reported outcomes.**
Laura Mustata

**P111. A Multicentre Audit on Chest Wall Perforator Flaps for Partial Breast Reconstruction in Breast Cancer**
Mihir Chandarana

**P112. Oncoplastic conservation for cT3 or multifocal / multicentric cancers (extreme oncoplasty) is oncologically safe**
Laszlo Romics

**P113. Baseline Volume and Surface Asymmetry using 3D Surface Imaging (3D-SI) in a Breast Conserving Treatment (BCT) Population.**
Amy Godden

**P114. The introduction of a breast implant surgical checklist reduces implant loss rate**
Sam Meadows

**P115. Patient reported outcomes after lipofilling**
Victoria Rusius

**P116. Climbing the Learning Curve with Chest Wall Perforator flaps**
Samantha Williams

**P117. TIGR Matrix synthetic long-term resorbable mesh for pre-pectoral and sub-pectoral implant based breast reconstruction: outcomes of two years practice**
Giulio Cuffolo

**P118. Polyurethane Implants: Time to leave the ADM on the shelf?**
John Wild

**P119. Designing a definitive randomised clinical trial in implant-based breast reconstruction: A qualitative study.**
Gareth Davies

**P120. Immediate Reconstruction Following Mastectomy For Breast Cancer: Long-term outcomes from a Single Institution**
Liusaidh McClymont

**P121. Thermal Imaging in Perforator DIEP Flap Reconstruction**
Karinn Farquharson

**P122. Permissive breast reconstruction and implant loss. A delicate balance and an ethical challenge.**
Jason Saunders

**P123. Evaluating correlation between age and the axillary lymph node cortical thickness (ALNCT) on ultrasound, in patients attending the symptomatic breast clinic, with no cancer or any condition resulting in reactive nodes.**
Lubna Khalid

**P124. Avoiding surgery in breast cancer patients with exceptional Response to neo-adjuvant chemotherapy - ASTARTE Trial**
Marios Konstantinos Tasoulis

**P125. Clinical Management of Breast Patients with Proven BRCA1, BRCA2 or TP53 mutation in NHS Tayside**
Pavithran Maniam

**P126. Impact of single use negative pressure wound therapy on surgical incisions following breast surgery: a multi-centre evaluation**
Catherine Whittall

**P127. Impact of Oncotype DX Test on the use of adjuvant chemotherapy in early breast cancer over 5 years in Oxford, UK**
Akriti Nanda

**P128. Reducing the Burden of Research: a Feasibility Study of a Novel Online Study Design for use in a Multi-Centre Study.**
Amy Godden

**P129. Improving Breast Cancer Patient Experience Through Innovative Design Thinking**
Daniel Leff

**P130. An analysis of screen-detected breast cancers in Leeds Teaching Hospital Trust, focussing on concordance in histological grading and other key prognostic factors**
Megan Miscampbell

**P131. Does rapid access to BRCA testing change surgical decision-making in newly diagnosed breast cancer patients?**
Quratul Ain

**P132. Is socioeconomic status a barrier for individual breast cancer awareness related knowledge in developing countries ?**
Agnimita Giri Sarkar

**P133. Supporting Survivors to Manage their Cancer Surveillance: Not Merely a Reallocation of Resources**
Ian Whitehead

**P134. Adequacy of post-operative analgesia following day case breast surgery**
Freyia Mahon-Daly

**P135. Symptomatic breast clinic patients value provision of a detailed core biopsy leaflet prior to attending clinic**
Jennifer Pollard

**P136. Does complete radiological response correlate with a complete pathological response following neoadjuavant chemotherapy?**
Alexander Frost-Younger

**P137. A Retrospective Analysis of Pleomorphic Lobular Carcinoma In Situ**
Maneesha Patwardhan

**P138. Can tumour infiltrating lymphocytes (TILs) predict the response of neoadjuvant chemotherapy in triple negative breast cancer?**
Quratul Ain

**P139. An Audit of the Management of Breast Cancer in Women Aged Less Than 40 Against BCY3 Guidelines in a Tertiary Breast Unit.**
Rachel Heard

**P140. To Stage or not to Stage before Neoadjuvant Chemotherapy?**
Sadaf Jafferbhoy

**P141. Further investigations during follow up of breast cancer patients treated with curative intent**
Kirti Katherine Kabeer

**P142. Postoperative wound complications after immediate breast reconstruction increase recurrence rate in ER negative patients**
Laszlo Romics

**P143. Immune microenvironment as a prognostic marker of recurrence following breast conserving surgery for DCIS**
Rajiv Dave

**P144. Factors Associated with Breast Cancer Recurrence in a District General Hospital**
Sanya Patel

**P145. PONDx breast cancer recurrence score: a significant adjunct to standard parameters and its role in reducing the uptake of chemotherapy. A single centre experience.**
Emily Britton

**P146. Study of breast cancer presentation and triple negative status in Bangladeshi women resident in the UK compared to those living in Bangladesh**
Amine Awad

**P147. Body composition and chemotherapy toxicities – the BeGIN study**
Adam Heetun

**P148. Application of Neo-Bioscore to predict survival in breast cancer patients receiving Neoadjuvant chemotherapy.**
Asma Munir

**P149. The One-Stop Clinic is an Opportunity to Assess Breast Cancer Risk and Offer Advice Targeting Modifiable Risk Factors.**
Amy Godden

**P150. Direct-to-implant, prepectoral breast reconstruction: a single institution experience.**
Victoria Teoh

**P151. Does Pre-pectoral Reconstruction (P-PR) Reduce Early Post-operative (P-OP)And Late Neuropathic Pain (NP)?**
Rachel Soulsby

**P152. A DGH’s experience using Magseed as a localisation tool for impalpable breast lesions**
Jasmine Crane

**P153. Lipomodelling at Chesterfield Royal Hospital: Service review in a District General Hospital using Lipomodelling Guidelines for Breast Surgery (2012).**
Chris Busby

**P154. Incidence of Blue Dye Associated Anaphylaxis in Sentinel Lymph Node Biopsy**
Nada Elsaid

**P155. “Medial wing Hemi-mastopexy”: An innovation to avoid medial pole emptiness in reduction mammaplasty**
Emanuele Garreffa

**P156. Analysis of Patient Anxiety related to Magseed and Guide-wire localisation techniques**
sarah small

**P157. The use of Magnetic Seeds for Lesion Localisation in Breast Surgery – The North Wales Experience**
Mandana Pennick

**P158. Pedicled Perforator Flap – A District General Hospital’s Experience**
Gwen Bromley

**P159. Margin re-excision rates following wide local excision with surgeon-operated intraoperative ultrasound.**
James Worsfold